Bausch Health Companies Inc. is a global, diversified pharmaceutical company. The Salix segment includes sales in the U.S. of GI products. The International segment includes sales of Bausch + Lomb products and Solta Medical aesthetic medical devices, outside the U.S. and Puerto Rico of branded pharmaceutical products, branded generic pharmaceutical products and OTC products. The Solta Medical segment includes global sales of Solta Medical aesthetic medical devices. The Diversified segment includes sales in the U.S. of pharmaceutical products in the areas of neurology and certain other therapeutic classes, dermatology products, generic pharmaceutical products and dentistry products. The Bausch + Lomb segment includes global sales of Bausch + Lomb Vision Care, Surgical and Pharmaceuticals products. Its drug candidate, Larsucosterol binds to and inhibits the activity of DNA methyltransferases, epigenetic enzymes that are elevated and associated with hypermethylation found in AH patients.
높은 성장
회사의 매출은 지난 3년간 꾸준히 성장해왔으며, 연평균 17.23%의 증가율을 기록했습니다.
이익 전환
회사의 실적이 흑자로 전환되어, 최근 연간 순이익은 미화 달러에 달합니다.
과대 평가된
회사의 최신 PE은 -1.47로, 최근 3년 기준 높은 백분위 범위에 속합니다.
기관 매도
최신 기관 보유 주식 수는 173.34M주이며, 전 분기 대비 27.12% 감소했습니다.
시장 활동 증가
회사는 투자자들의 관심이 높아져, 최근 20일간 회전율이 0.34입니다.